Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
Cortes, Jorge E., Jiang, Qian, Wang, Jianxiang, Weng, Jianyu, Zhu, Huanling, Liu, Xiaoli, Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald, Savona, Michael, Martin-Regueira, Patricia, Sy, Oumar, GurnJournal:
Leukemia
DOI:
10.1038/s41375-020-0805-1
Date:
April, 2020
File:
PDF, 1022 KB
2020